Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CinnaGen galcanezumab versus Emgality in treatment-resistant migraine
IRCT20150303021315N41Phase 3Recruiting
- Sponsor
- CinnaGen
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of galcanezumab in migraine (2 arms), sponsored by CinnaGen. Primary endpoints: Number of Migraine Headache Days and Number of Headache Days. Started Feb 2026; status: recruiting.
02
Drugs
galcanezumab
03
Conditions
migraine
Beyond the preview
Go deeper on IRCT20150303021315N41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150303021315N41.